Efdoralprin alfa, a recombinant human alpha-1 antitrypsin (AAT)-Fc fusion protein, showed superior efficacy to standard plasma-derived therapy in adults with AATD
GS-098, a first-in-class, humanized monoclonal antibody targeting the thyroid-stimulating hormone receptor, is designed to rapidly block the pathogenic activity of thyroid-stimulating autoantibodies
The upcoming trials will evaluate both active and chronic TED in randomized, double-blind, placebo-controlled studies
Alphyn is developing Zabalafin Hydrogel as the first therapy to simultaneously tackle the interconnected drivers of AD
The companies aim to expand treatment options for millions living with metabolic disorders
The company has unveiled the results of pirtobrutinib from its BRUIN CLL-313 study
Alport Syndrome is caused by genetic mutations affecting type IV collagen in the kidneys, ears, and eyes
Here's a new ray of hope for new hope for patients suffering from Meniere’s disease (MD) and sensorineural hearing loss
Seeing well-controlled Phase 3 data that shows a marked slowing of lesion growth in Stargardt disease is deeply encouraging
Pfizer and Valneva have been collaborating on VLA15’s development and commercialization since April 2020
Subscribe To Our Newsletter & Stay Updated
